Skip to main content
Resverlogix Corp. logo

Resverlogix Corp. — Investor Relations & Filings

Ticker · RVX ISIN · CA76128M1086 LEI · 529900VI46SAPCOSH758 TSX Real estate activities
Open in API
Filings indexed 195 across all filing types
Latest filing 2026-04-20 Regulatory Filings
Country CA Canada
Listing TSX RVX

About Resverlogix Corp.

https://www.resverlogix.com/

Resverlogix Corp. is a late-stage clinical biotechnology company specializing in the development of epigenetic therapies for chronic illnesses. The company's core scientific focus involves regulating the expression of disease-causing genes. Its lead drug candidate is Apabetalone, a small molecule inhibitor currently being advanced through clinical programs, including the BETonMACE trial. Apabetalone is primarily targeted toward treating cardiovascular diseases and complications associated with diabetes mellitus. Resverlogix aims to provide novel science and value-based health solutions to key stakeholders, including pharmaceutical companies, physicians, and health payer groups.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Regulatory Filings
2026-04-20 English
Notice of the meeting and record date - English.pdf
Regulatory Filings
2026-04-20 English
News release - English.pdf
Report Publication Announcement Classification · 1% confidence The document is a news release announcing that Resverlogix has filed its audited financial statements, MD&A, certifications, and annual information form for the 2025 year end, as well as the revocation of an MCTO. It does not contain the actual filings themselves but is an announcement of their publication. It is brief (under 5,000 characters) and refers readers to SEDAR for the filings. This matches the “Report Publication Announcement (RPA)” category.
2026-04-16 English
News release - English.pdf
Report Publication Announcement Classification · 1% confidence The document is a brief press release announcing that Resverlogix Corp. has filed its audited financial statements, MD&A, certifications of annual filings, and annual information form for the year ended December 31, 2025, and the revocation of a management cease trade order. It does not contain the substantive annual report itself but rather informs stakeholders of its publication and filing status. Under the “menu vs. meal” rule, this constitutes a Report Publication Announcement (RPA), not the full report.
2026-04-16 English
52-109F1 - Certification of annual filings - CFO (E).pdf
Audit Report / Information Classification · 1% confidence The document is a standalone certification (Form 52-109F1) by the CFO regarding the annual filings, disclosure controls and internal controls over financial reporting, as required under National Instrument 52-109. It is not the Annual Report itself, nor an announcement, earnings release, or other category. It constitutes audit-related information/certification rather than full financial statements or management’s MD&A. Therefore, it best fits the “Audit Report / Information” category. FY 2025
2026-04-11 English
52-109F1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109F1 “Certification of Annual Filings” under Canadian NI 52-109, signed by the CEO, certifying the issuer’s annual filings. It is not the annual report itself, nor an audit report, earnings release or other specific category. It is a regulatory filing form, which falls under the fallback “Regulatory Filings (RNS).”
2026-04-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.